Program
repotrectinib
Also written as “Repotrectinib”, “Oral repotrectinib (TPX-0005)” and “TPX-0005”.
Its studies are mostly in Neoplasm Metastasis · Lymphoma · Carcinoma, Non-Small-Cell Lung · Sarcoma · Lymphoma, Follicular, led by Bristol-Myers Squibb.
Furthest: phase 3, since Nov 15, 20239 company-led studies, 3 open or runningNext primary completion: Feb 16, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 93 open or running | phase 3since Nov 15, 2023 | Mar 6, 2017 | Feb 16, 2027phase 3 · NCT06140836 |
Also a collaborator on its studies: Zai Lab.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 6, 2017First study: phase 2 study in SarcomaFirst studyNCT03093116 · 500 planned · United States, Australia, Belgium and more
- Sep 12, 2019Phase 2 study in LymphomaNCT04094610 · 75 planned · United States, Australia, Canada and more
- Sep 13, 2021Phase 2 study in Neoplasm MetastasisNCT05071183 · 9 enrolled · United States
- Mar 28, 20232 phase 1 studies in Neoplasm MetastasisNCT05828303, NCT05828277
- Nov 15, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06140836 · 190 enrolled · United States, Argentina, Austria and more
- Apr 3, 2024Phase 1 study in Lymphoma, FollicularNCT06352528 · 18 enrolled · United States
- Jun 25, 2024Phase 1 study in Healthy VolunteersNCT06493409 · 32 enrolled · United States
- Oct 30, 2025Phase 1 study in Healthy VolunteersNCT07223671 · 30 enrolled · United States
Ahead
- Feb 16, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06140836
- Feb 29, 2028Primary completion: phase 2 study in SarcomaNCT03093116
TargetBeta
“An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, the proto-oncogene SRC, and focal adhesion kinase (FAK), ”NCIt, by rule
“Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor; NT-3 growth factor receptor inhibitor”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07223671Healthy Volunteers · United States | 1 | Completed | Feb 19, 2026 | 30 |
| NCT06493409Healthy Volunteers · United States | 1 | Completed | Dec 7, 2024 | 32 |
| NCT06352528Lymphoma, Follicular · United States | 1 | Completed | Sep 16, 2025 | 18 |
| NCT06140836Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 3 | Active, not recruiting | Feb 16, 2027 | 190 |
| NCT05828303Neoplasm Metastasis · United States, Australia, Brazil and more | 1 | Withdrawn | Jul 31, 2025 | 0 |
| NCT05828277Neoplasm Metastasis · United States, Spain | 1 | Withdrawn | Aug 31, 2025 | 0 |
| NCT05071183Neoplasm Metastasis · United States | 2 | Terminated | Mar 1, 2023 | 9 |
| NCT04094610Lymphoma · United States, Australia, Canada and more | 2 | Recruiting | Sep 30, 2026 | 75 |
| NCT03093116Sarcoma · United States, Australia, Belgium and more | 2 | Recruiting | Feb 29, 2028 | 500 |
How it is read
Names in the registry
- “Repotrectinib”, 4 entries
- “Oral repotrectinib (TPX-0005)”, 2 entries
- “TPX-0005”, 2 entries
- “repotrectinib (TPX-0005)”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 3 studies
- Lymphoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Sarcoma, 1 study
- Lymphoma, Follicular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.